Is MariMed A Safe Haven In The Wake Of Florida's Cannabis Legalization Defeat?
Cannabis company MariMed Inc. MRMD released its Q3 2024 results on November 6, announcing revised guidance for the fiscal year. While the company expects an 18–20% decline in EBITDA – down from its prior projection of flat to 2% growth – it raised its sales guidance to a 6–8% increase, up from 5–7%.
MariMed Inc. (MRMD) Q3 2024 Earnings Call Transcript
MariMed Inc. (OTCQX:MRMD) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Steve West - Vice President, Investor Relations Jon Levine - Chief Executive Officer Ryan Crandall - Chief Revenue Officer Tim Shaw - Chief Operating Officer Mario Pinho - Chief Financial Officer Conference Call Participants Pablo Zuanic - Zuanic Associates Andrew Semple - Ventum Financial Jesse Redmond - Water Tower Research William McNarland - TDR Research Operator Good morning. My name is Nicole, and I will be your lead operator for today.
Can MariMed's $7.7M Illinois Cannabis Expansion Turn The Tide In A $496M Market?
In Zuanic & Associates' latest equity report, senior analyst Pablo Zuanic analyzes MariMed's MRMD performance across its core markets, with Illinois (IL) accounting for 40-45% of the company's sales.
MariMed succeeds with growth strategy prioritizing conservatism over quick wins
MariMed (OTCQX:MRMD) has captured opportunities across the cannabis value chain with its “seed-to-sale” approach, encompassing flower cultivation, product development, marketing and distribution, and retail operations in key cannabis growth markets in the US. Importantly, the company chose a deliberate and evenly paced approach over the lure of rapid expansion to reach this point.
